Literature DB >> 33921446

Where and Why Modeling Amyotrophic Lateral Sclerosis.

Francesco Liguori1, Susanna Amadio1, Cinzia Volonté1,2.   

Abstract

Over the years, researchers have leveraged a host of different in vivo models in order to dissect amyotrophic lateral sclerosis (ALS), a neurodegenerative/neuroinflammatory disease that is heterogeneous in its clinical presentation and is multigenic, multifactorial and non-cell autonomous. These models include both vertebrates and invertebrates such as yeast, worms, flies, zebrafish, mice, rats, guinea pigs, dogs and, more recently, non-human primates. Despite their obvious differences and peculiarities, only the concurrent and comparative analysis of these various systems will allow the untangling of the causes and mechanisms of ALS for finally obtaining new efficacious therapeutics. However, harnessing these powerful organisms poses numerous challenges. In this context, we present here an updated and comprehensive review of how eukaryotic unicellular and multicellular organisms that reproduce a few of the main clinical features of the disease have helped in ALS research to dissect the pathological pathways of the disease insurgence and progression. We describe common features as well as discrepancies among these models, highlighting new insights and emerging roles for experimental organisms in ALS.

Entities:  

Keywords:  Caenorhabditis elegans; Danio rerio; Drosophila melanogaster; Saccharomyces cerevisiae; amyotrophic lateral sclerosis; animal modeling; canines; non-human primates; rodents

Year:  2021        PMID: 33921446     DOI: 10.3390/ijms22083977

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  8 in total

1.  Boosting the peripheral immune response in the skeletal muscles improved motor function in ALS transgenic mice.

Authors:  Maria Chiara Trolese; Carlotta Scarpa; Valentina Melfi; Paola Fabbrizio; Francesca Sironi; Martina Rossi; Caterina Bendotti; Giovanni Nardo
Journal:  Mol Ther       Date:  2022-04-27       Impact factor: 12.910

2.  New Insights into and Emerging Roles of Animal Models for Neurological Disorders.

Authors:  Changjong Moon
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

Review 3.  Fly for ALS: Drosophila modeling on the route to amyotrophic lateral sclerosis modifiers.

Authors:  Francesco Liguori; Susanna Amadio; Cinzia Volonté
Journal:  Cell Mol Life Sci       Date:  2021-07-28       Impact factor: 9.261

Review 4.  Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives.

Authors:  Tiziana Bonifacino; Roberta Arianna Zerbo; Matilde Balbi; Carola Torazza; Giulia Frumento; Ernesto Fedele; Giambattista Bonanno; Marco Milanese
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

5.  Retinoic Acid-Differentiated Neuroblastoma SH-SY5Y Is an Accessible In Vitro Model to Study Native Human Acid-Sensing Ion Channels 1a (ASIC1a).

Authors:  Aleksandr P Kalinovskii; Dmitry I Osmakov; Sergey G Koshelev; Kseniya I Lubova; Yuliya V Korolkova; Sergey A Kozlov; Yaroslav A Andreev
Journal:  Biology (Basel)       Date:  2022-01-20

6.  The mechanism of action of a novel neuroprotective low molecular weight dextran sulphate: New platform therapy for neurodegenerative diseases like Amyotrophic Lateral Sclerosis.

Authors:  Ann Logan; Antonio Belli; Valentina Di Pietro; Barbara Tavazzi; Giacomo Lazzarino; Renata Mangione; Giuseppe Lazzarino; Inés Morano; Omar Qureshi; Lars Bruce; Nicholas M Barnes; Zsuzsanna Nagy
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

7.  SOD-1 Variants in Amyotrophic Lateral Sclerosis: Systematic Re-Evaluation According to ACMG-AMP Guidelines.

Authors:  Paola Ruffo; Benedetta Perrone; Francesca Luisa Conforti
Journal:  Genes (Basel)       Date:  2022-03-18       Impact factor: 4.096

Review 8.  Organ on a Chip: A Novel in vitro Biomimetic Strategy in Amyotrophic Lateral Sclerosis (ALS) Modeling.

Authors:  Babak Arjmand; Shayesteh Kokabi Hamidpour; Zahra Rabbani; Akram Tayanloo-Beik; Fakher Rahim; Hamid Reza Aghayan; Bagher Larijani
Journal:  Front Neurol       Date:  2022-01-17       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.